GLP-1s
BankingMeat snacks have emerged as the clear winner in America’s seismic GLP-1 consumption shift, while popcorn is down
By Nick LichtenbergFebruary 10, 2026
By Tara ComonteFebruary 9, 2026
C-SuitePfizer CEO on how he struck a deal with President Trump in 10 days to lower American drug costs
By Fortune EditorsJanuary 27, 2026
HealthGLP-1s could end up being ‘the first true longevity drug’ as the world battles a rising obesity crisis
By Angelica AngNovember 21, 2025
C-SuiteRay Dalio is backing a $1 billion blueberry unicorn that sells berries nearly the size of golf balls
By Eva RoytburgNovember 4, 2025
HealthAdult obesity rate fell from record high—and big pharma is reaping the benefits from mainstream sales of weight-loss drugs like Zepound and Mounjaro
By Matty Merritt and Morning BrewOctober 31, 2025
EconomyThe ‘quiet alarm bell’ on U.S. health costs: Employers are backed into a corner, and workers are paying the price
By Ashley LutzOctober 22, 2025
CommentaryTrump wants Medicare to pay for your Ozempic treatment. Taxpayers may foot the bill for billions in fraud
By Ari Yampolsky and Max VoldmanAugust 12, 2025
NewslettersExclusive: The founders of SoulCycle built a startup for relationships, then pivoted to GLP-1 support groups. Now its assets are being acquired by WeightWatchers
By Emma HinchliffeAugust 7, 2025
By Michelle Amponsah and BloombergJune 20, 2025
By Beth GreenfieldJune 5, 2025
HealthThe Ozempic boom could be bad news for restaurants as more than half of GLP-1 users report cutting back on dining out, report finds
By Sasha RogelbergJune 4, 2025
